If you have been reading about c-Met and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-24. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Hydrophobic membranes are often polydimethylsiloxane based where the actual separation mechanism is based on the solution-diffusion model described above. Hydrophilic membranes are more widely available. The commercially most successful pervaporation membrane system to date is based on polyvinyl alcohol. More recently also membranes based on polyimide have become available. To overcome the intrinsic disadvantages of polymeric membrane systems ceramic membranes have been developed over the last decade. These ceramic membranes consist of nanoporous layers on top of a macroporous support. The pores must be large enough to let water molecules pass through and retain any other solvents that have a larger molecular size such as ethanol. As a result, a molecular sieve with a pore size of about 4 Å is obtained. The most widely available member of this class of membranes is that based on zeolite A. Alternatively to these crystalline materials, the porous structure of amorphous silica layers can be tailored towards molecular selectivity. These membranes are fabricated by sol-gel chemical processes. Research into novel hydrophilic ceramic membranes has been focused on titania or zirconia. Very recently a break-through in hydrothermal stability has been achieved through the development of an organic-inorganic hybrid material.
12(S)-HpETE and 12(S)-HETE induce itching responses when injected into the skin of mice; this has led to the suggestion that these metabolites contribute to the itching (i.e. clinical pruritus) which accompanies such conditions as atopic dermatitis, contact dermatitis, urticaria, chronic renal failure, and cholestasis. Since it mediates 12(S)-HETE-induced itching in the mouse model, BLT2 rather than GPR31 may mediate human itch in these reactions.
Seizures are characterized by high levels of synchronized neuronal activity. One important regulator of neuronal activity is the hyperpolarizing A-type current mediated by potassium channel KV4.2. miR-324-5p downregulates KV4.2, exacerbating conditions that lead to seizure onset, and downregulation of miR-324-5p in mouse models of epilepsy is seizure-suppressive. Changes in miRNA expression are seen in epileptogenesis and in other disease pathologies. In epilepsy, miR-324-5p expression has been shown to increase and decrease at different timepoints and loci. Importantly, miR-324-5p has increased association with the RISC complex following seizure in mice, indicating more suppressive activity. Overall, this suggests that miR-324-5p plays a role in epileptogenesis via targeting of potassium channel KV4.2. miR-324-5p contributes to cardiac disease pathophysiology and cardiomyocite death through translational inhibition of Mtfr1, leading to reduced mitochondrial fission, apoptosis, and myocardial infarction.
== Use in healthcare == Medical researchers have studied the use of virtual reality games in healthcare. For example, meta-analyses have demonstrated that virtual reality games could be used for stress management or to improve cognitive and physical functions among elderly post-stroke patients.
Sources: en.wikipedia.org
This list of sequenced animal genomes contains animal species for which complete genome sequences have been assembled, annotated and published. Substantially complete draft genomes are included, but not partial genome sequences or organelle-only sequences. For all kingdoms, see the list of sequenced genomes.
== Prevention == Early and effective breastfeeding can minimize the likelihood of engorgement, latch difficulties, nipple trauma and bacterial infections. The surface of the nipple and breast pumps should be sterilized to remove sources of irritants before breastfeeding or pumping of milk. It may help prevent yeast infections and cross-contamination of bacteria between family members. Ideally, cleaning baby items and mothers' underwear like boiling or disinfecting pacifiers, diapers, bras and bathing equipment frequently can prevent infections. During breastfeeding, mothers should hold infants in the correct breastfeeding position in order to prevent nipple pain brought by poor positioning.
==== Modified cellulose adhesives ==== These water-compatible adhesives are appropriate for treatments requiring a light bond. Klucel G, carboxymethyl cellulose, and methylcellulose are the most common.
=== Heart rate and energy expenditure === Studies have shown that compared to wild type mice, Ffar3 gene knockout mice have: a) significantly smaller-sized sympathetic nervous system ganglia as judged by measurements of this systems' largest ganglia, the superior cervical ganglion; b) significantly slower heart rates; and c) significantly lower norepinephrine levels in their blood plasma. (Norepinephrine is a neurotransmitter that is released by sympathetic nervous system neurons and among other actions increases heart rate and total body energy expenditure.) Furthermore, the treatment of wild type mice with propionic acid increased their heart rates but did not do so in Ffar3 gene knockout mice. Finally, the offspring of Ffar3-gene knockout mice had slower heart rates (as well as lower body temperatures) than the offspring of wild type mice. These findings indicate that FFAR3 regulates heart rates and energy expenditure in mice. Studies are needed to determine if it does so in humans.
=== Antifouling material for industry === Some algicidal bacterial species produce bioactive compounds that have potential applications in antifouling coatings for ship hulls and aquaculture facilities. These compounds can inhibit the growth and attachment of algae and other microorganisms on submerged surfaces, reducing biofouling. They are still under investigation and can potentially be an environmentally friendly alternative to the traditional chemical anti-fouling paints.
Sources: en.wikipedia.org
Harrison (1912–1998), American chemist who studied the structure of organic compounds and their interaction with light, first woman President of the American Chemical Society Odd Hassel (1897–1981), Norwegian chemist who established the three-dimensionality of molecular geometry, 1969 Nobel Prize in chemistry Charles Hatchett (1765–1847), English chemist who discovered niobium Herbert A. Hauptman (1917–2011), American mathematician who developed a method that opened a new era in research in determination of molecular structures of crystallized materials, 1985 Nobel Prize in chemistry Walter Hawkins (1911–1992), American chemist, a pioneer of polymer chemistry, who co-invented a polymer with antioxidants that prevented deterioration even in extreme temperatures Walter Haworth (1883–1950), British chemist, 1937 Nobel Prize in chemistry "for his investigations on carbohydrates and vitamin C" Sam Hay (PhD 2004), New Zealand chemist known for in silico enzymology, quantum mechanics roles in biological processes Alma Levant Hayden (1927–1967), American spectrophotometrist known for showing that Krebiozen was a quack anti-cancer agent Jabir Ibn Hayyan (722–804), Persian-Arab chemist and alchemist, purported author of many works in Arabic
== Epidemiology == Globally, the prevalence and incidence of pulmonary fibrosis has been studied in the United States, Norway, Czech Republic, Greece, United Kingdom, Finland, and Turkey, with only two studies in Japan and Taiwan. But most of these studies were of people already diagnosed with pulmonary fibrosis, which lowers the diagnosis sensitivity, so that the prevalence and incidence has ranged from 0.7 per 100,000 in Taiwan to 63.0 per 100,000 in the U.S., and the published incidence has ranged from 0.6 per 100,000 person years to 17.4 per 100,000 person years. The mean age of all pulmonary fibrosis patients is between 65 and 70 years, making age a criterion of its own. Aging respiratory systems are much more vulnerable to fibrosis and stem cell depletion.
The amplitude of an action potential is often thought to be independent of the amount of current that produced it. In other words, larger currents do not create larger action potentials. Therefore, action potentials are said to be all-or-none signals, since either they occur fully or they do not occur at all. This is in contrast to receptor potentials, whose amplitudes are dependent on the intensity of a stimulus. In both cases, the frequency of action potentials is correlated with the intensity of a stimulus. Despite the classical view of the action potential as a stereotyped, uniform signal having dominated the field of neuroscience for many decades, newer evidence does suggest that action potentials are more complex events indeed capable of transmitting information through not just their amplitude, but their duration and phase as well, sometimes even up to distances originally not thought to be possible.
== Senegal and Mauritania == El Hadj Umar Tall (1797–1864) – religious leader from the Tijani Sufi Order from Senegal. Founder of the Toucouleur Empire Ahmadou Tall (1836–1897) – Second Sultan of the Toucouleur Empire Sulayman Bal (1726–1776) – Islamic scholar and war commander from the Futa Toro in Senegal Macky Sall – former president of Senegal; Chairman of the African Union Abdoulaye Baldé (politician)- Politician, former secretary-general of the presidency, Mayor of Ziguinchor, Senegal Abdoulaye Saydou Sow - Former Minister of Urban Planning, Housing and Public Hygiene Abdou Rachid Thiam - Biophysicist, research director at French National Centre for Scientific Research. Abdourahmane Sow- Politician, former Minister and former vice-president of the National Assembly Senegal. Abou Lô - Former Minister of Communication, Telecommunications and ICT, Senegal. Abdoulaye Bibi Baldé - Former Minister of Communication, Telecommunications, Posts and Digital Ecosystem Ahmadou Bamba Ba – Religious leader, Senegal Amadou Kane - Former Minister of Economy and Finance, Senegal. Amadou-Mahtar M'Bow - Former director general of UNESCO, First African to Lead a Global Institution. Mame Madior Boye - First Female prime minister of Senegal. Aïssata Kane – former Mauritanian politician who was the country's first female government minister and women's rights activist. Amadou Ba- Politician. Current prime minister, former minister of foreign affairs, former Minister of Economy and Finance, Senegal Amadou Hott - Senegalese economist.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.